Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: A pilot study in healthy subjects

Human Immunology

Volumn 76, Issue 10, 2015, Pages 747-752

  Cosentino, Marco ^a   Ferrari, Marco ^a   Kustrimovic, Natasa ^a   Rasini, Emanuela ^a   Marino, Franca ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Dopaminergic receptors; Gene polymorphisms; Neuroimmunology; T lymphocytes

Indexed keywords

DOPAMINE RECEPTOR; CD3 ANTIGEN; ISOPROTEIN;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CIRCULATING T LYMPHOCYTE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHOCYTE COUNT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VARIABLE NUMBER OF TANDEM REPEAT; CYTOLOGY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MIDDLE AGED; PILOT STUDY;

AGED; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE;

EID: 84945534288     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.09.032     Document Type: Article

References (44)

1. Levite M. Dopamine in the immune system: dopamine receptors in immune cells, potent effects, endogenous production and involvement in immune and neuropsychiatric diseases. Nerve-driven-immunity - Neurotransmitters and Neuropeptides in the Immune System 2012, 1-45. Springer-Verlag, Wien. M. Levite (Ed.).
2. Sarkar C., Chakroborty D., Basu S. Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. J. Neuroimmune Pharmacol. 2013, 8:7-14.
3. Cosentino M., Fietta A.M., Ferrari M., Rasini E., Bombelli R., Carcano E., Saporiti F., Meloni F., Marino F., Lecchini S. Human CD4+ CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007, 109:632-642.
4. Nakano K., Higashi T., Takagi R., Hashimoto K., Tanaka Y., Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int. Immunol. 2009, 21:645-654.
5. Beaulieu J.-M., Gainetdinov R.R. The physiology, signalling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
6. Kustrimovic N., Rasini E., Legnaro M., Marino F., Cosentino M. Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease. J. Neuroimmune Pharmacol. 2014, 9:302-312.
7. Wong A.H., Buckle C.E., Van Tol H.H. Polymorphisms in dopamine receptors: what do they tell us?. Eur. J. Pharmacol. 2000, 410:183-203.
8. McAllister T.W., Summerall L. Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders. Curr. Psychiatry Rep. 2003, 5:400-409.
9. D'Souza U.M., Craig I.W. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog. Brain Res. 2008, 172:73-98.
10. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 2009, 20:1-17.
11. George S.R., Cheng R., Nguyen T., Israel Y., O'Dowd B.F. Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism. Biochem. Biophys. Res. Commun. 1993, 196:107-114.
12. Huang W., Ma J.Z., Payne T.J., Beuten J., Dupont R.T., Li M.D. Significant association of DRD1 with nicotine dependence. Hum. Genet. 2008, 123:133-140.
13. Novak G., LeBlanc M., Zai C., Shaikh S., Renou J., DeLuca V., Bulgin N., Kennedy J.L., Le Foll B. Association of polymorphisms in the BDNF, DRD1 and DRD3 genes with tobacco smoking in schizophrenia. Ann. Hum. Genet. 2010, 74:291-298.
14. Prasad P., Ambekar A., Vaswani M. Case-control association analysis of dopamine receptor polymorphisms in alcohol dependence: a pilot study in Indian males. BMC Res. Notes 2013, 6:418.
15. Batel P., Houchi H., Daoust M., Ramoz N., Naassila M., Gorwood P. A haplotype of the DRD1 gene is associated with alcohol dependence. Alcohol Clin. Exp. Res. 2008, 32:567-572.
16. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997, 7:479-484.
17. Pohjalainen T., Rinne J.O., Någren K., Lehikoinen P., Anttila K., Syvälahti E.K., Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 1998, 3:256-260.
18. Jönsson E.G., Nöthen M.M., Grünhage F., Farde L., Nakashima Y., Propping P., Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999, 4:290-296.
19. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., Gejman P.V. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 2003, 12:205-216.
20. Hirvonen M.M., Lumme V., Hirvonen J., Pesonen U., Någren K., Vahlberg T., Scheinin H., Hietala J. C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:630-636.
21. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 1996, 225:1068-1072.
22. Kang S.G., Lee B.H., Lee J.S., Chai Y.G., Ko K.P., Lee H.J., Han D.M., Ji H., Jang G.H., Shin H.E. DRD3 gene rs6280 polymorphism may be associated with alcohol dependence overall and with lesch type I alcohol dependence in Koreans. Neuropsychobiology 2014, 69:140-146.
23. Kuo S.C., Yeh Y.W., Chen C.Y., Huang C.C., Chang H.A., Yen C.H., Ho P.S., Liang C.S., Chou H.W., Lu R.B., Huang S.Y. DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 51:1-8.
24. Simpson J., Vetuz G., Wilson M., Brookes K.J., Kent L. The DRD4 receptor Exon 3 VNTR and 5' SNP variants and mRNA expression in human post-mortem brain tissue. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:1228-1233.
25. Vereczkei A., Demetrovics Z., Szekely A., Sarkozy P., Antal P., Szilagyi A., Sasvari-Szekely M., Barta C. Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence. PLoS One 2013, 8:e66592.
26. Ptácek R., Kuzelová H., Stefano G.B. Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Med.Sci. Monit. 2011, 17:RA215-RA220.
27. Cosentino M., Marino F., Maestroni G.J.M. Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives. Front. Cell. Neurosci. 2015, 9:302. 10.3389/fncel.2015.00302.
28. Marino F., Cosentino M., Bombelli R., Ferrari M., Maestroni G.J., Conti A., Lecchini S., Frigo G. Measurement of catecholamines in mouse bone marrow by means of HPLC with electrochemical detection. Haematologica 1997, 82:392-394.
29. Maestroni G.J., Cosentino M., Marino F., Togni M., Conti A., Lecchini S., Frigo G. Neural and endogenous catecholamines in the bone marrow. Circadian association of norepinephrine with hematopoiesis?. Exp. Hematol. 1998, 26:1172-1177.
30. Cosentino M., Marino F., Bombelli R., Ferrari M., Maestroni G.J., Conti A., Rasini E., Lecchini S., Frigo G. Association between the circadian course of endogenous noradrenaline and the hematopoietic cell cycle in mouse bone marrow. J. Chemother. 1998, 10:179-181.
31. Spiegel A., Shivtiel S., Kalinkovich A., Ludin A., Netzer N., Goichberg P., Azaria Y., Resnick I., Hardan I., Ben-Hur H., et al. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat. Immunol. 2007, 8:1123-1131.
32. Cosentino M., Rasini E., Colombo C., Marino F., Blandini F., Ferrari M., Samuele A., Lecchini S., Nappi G., Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic. Biol. Med. 2004, 36:1233-1240.
33. Loseva E.V., Loginova N.A., Mezentseva M.V., Klodt P.M., Kudrin V.S. Immunological parameters of the blood and monoamine content in the brain of rats during long-term overcrowding. Bull. Exp. Biol. Med. 2013, 155:470-473.
34. Seay J.S., McIntosh R., Fekete E.M., Fletcher M.A., Kumar M., Schneiderman N., Antoni M.H. Self-reported sleep disturbance is associated with lower CD4 count and 24-h urinary dopamine levels in ethnic minority women living with HIV. Psychoneuroendocrinology 2013, 38:2647-2653.
35. Kumar A.M., Ownby R.L., Waldrop-Valverde D., Fernandez B., Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J. Neurovirol. 2011, 17:26-40.
36. Purohit V., Rapaka R., Frankenheim J., Avila A., Sorensen R., Rutter J. National Institute on Drug Abuse symposium report: drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. J. Neurovirol. 2013, 19:119-122.
37. Nakano K., Yamaoka K., Hanami K., Saito K., Sasaguri Y., Yanagihara N., Tanaka S., Katsuki I., Matsushita S., Tanaka Y. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23,390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J. Immunol. 2011, 186:3745-3752.
38. Prado C., Contreras F., Gonzalez H., Diaz P., Elgueta D., Barrientos M., Herrada A.A., Lladser A., Bernales S., Pacheco R. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J. Immunol. 2012, 188:3062-3070.
39. Franz D., Contreras F., González H., Prado C., Elgueta D., Figueroa C., Pacheco R. Dopamine receptors D3 and D5 regulate CD4+ T-cell activation and differentiation by modulating ERK activation and cAMP production. J. Neuroimmunol. 2015, 284:18-29.
40. Cosentino M., Zaffaroni M., Trojano M., Giorelli M., Pica C., Rasini E., Bombelli R., Ferrari M., Ghezzi A., Comi G., et al. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon- β therapy. Neuroimmunomodulation 2012, 19:283-292.
41. 5 in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis. J. Neuroimmunol. 2014, 277:193-196.
42. Robles A.I., Yang P., Jen J., McClary A.C., Calhoun K., Bowman E.D., Vähäkangas K., Greathouse K.L., Wang Y., Olivo-Marston S., et al. A DRD1 polymorphism predisposes to lung cancer among those exposed to secondhand smoke during childhood. Cancer Prev. Res. (Phila.) 2014, 7:1210-1218.
43. Sarkar C., Chakroborty D., Chowdhury U.R., Dasgupta P.S., Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14:2502-2510.
44. Sarkar C., Chakroborty D., Dasgupta P.S., Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. Int. J. Cancer 2015, 137:744-749.